This book discusses the most significant recent advances in oncological molecular imaging, covering the full spectrum from basic and preclinical research to clinical practice. The content is divided into five sections, the first of which is devoted to standardized and emerging technologies and probe designs for different modalities, such as PET, SPECT, optical and optoacoustic imaging, ultrasound, CT, and MRI. The second section focuses on multiscale preclinical applications ranging from advanced microscopy and mass spectroscopy to whole-body imaging. In the third section, various clinical applications are presented, including image-guided surgery and the radiomic analysis of multiple imaging features. The final two sections are dedicated to the emerging, crucial role that molecular imaging can play in the planning and monitoring of external and internal radiotherapy, and to future challenges and prospects in multimodality imaging. Given its scope, the handbook will benefit all readers who are interested in the revolution in diagnostic and therapeutic oncology that is now being brought about by molecular imaging.
You can buy this product with a few simple clicks and have the file in your user profile forever.
AUTHORS: Otmar SchoberFabian KiesslingJürgen Debus
YEAR: 2020
PAGES: 918
LANGUAGE: ENGLISH
PUBLICATION: Springer, Cham
ISBN: 978-3-030-42618-7
$53,00 Original price was: $53,00.$3,00Current price is: $3,00.
Product Related
-75%
The Cuckoo’s Nest: Exploring the World of Psychotherapy through Film Original PDF 2026
-96%
Confronting Mental Health Stigma with AI and Machine Learning Original PDF 2026
-91%
Practical Handbook of Advanced Interventional Cardiology: Tips and Tricks 6th Original PDF 2026
-92%
The Coaching Psychology Handbook: Integrating Psychological Theory, Practice and Research Original PDF 2026
-94%
Biochip Design and Health Informatics Using IoT and SDN Original PDF 2026
-83%
CBT Frontline Action for Long-Term Conditions and Palliative Care A Guide for Care Professionals 2nd Edition Original PDF 2026
-95%